Results 21 to 30 of about 7,465 (248)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +1 more source

Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma

, 2020
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI ...
Charles Kunos, Jacek Capala
core   +1 more source

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source

Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System

CHIMIA, 2020
Radiopharmacy at ETH has worked on the development of novel PET tracers for neuro-, cardiac- and tumor imaging for many years. In this paper, our efforts on targeting the glutamatergic system of the metabotropic glutamate receptor subtype 5 (mGluR5) and ...
Linjing Mu, Stefanie D. Kramer, Hazem Ahmed, Stefan Gruber, Susanne Geistlich, Roger Schibli, Simon M. Ametamey   +6 more
doaj   +1 more source

Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer

, 2021
Prostate-specific membrane antigen (PSMA) is a glycoprotein present in the prostate, that is overexpressed in prostate cancer (PCa). Recently, PSMA-directed radiopharmaceuticals have been developed, allowing the pinpointing of tumors with the Positron ...
Marcelo L. da Cunha, Leonardo L. Fuscaldi, Danielle V. Sobral, Jorge Mejia, Luciana Malavolta, Ana Claudia R. Durante, Ana Cláudia C. Miranda, Fernanda F. Mendonça, Marycel F. de Barboza   +8 more
core   +1 more source

Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)

Journal of Hematology & Oncology, 2022
The vast majority of our knowledge regarding cancer radiobiology and the activation of radioresistance mechanisms emerged from studies using external beam radiation therapy (EBRT).
Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli, Martin Behe   +8 more
doaj   +1 more source

Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer

, 2020
Financial toxicity or the debt a cancer survivor incurs from the costs of their medical cancer care is an understudied aspect in the clinical development of experimental therapeutic agents. The United States National Cancer Institute (NCI) Cancer Therapy
Rita Abdallah, Charles A. Kunos
core   +1 more source

Radiopharmaceuticals for treatment of adrenocortical carcinoma

, 2023
Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease.
Hartrampf, Philipp E., Kosmala, Aleksander, Wiebke Schlötelburg, Stefanie Hahner, Andreas K. Buck, Schlötelburg, Wiebke, Buck, Andreas K., Hahner, Stefanie, Schirbel, Andreas, Kerstin Michalski, Andreas Schirbel, Michalski, Kerstin, Philipp E. Hartrampf, Aleksander Kosmala   +13 more
core   +1 more source

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

, 2022
Purpose: Prostate cancer (PCa) is characterized by high expression of prostate-specific 1membrane antigen (PSMA), a type II transmembrane protein.
Luan, Xiaohui, Xiaojun Zhang, Jinming Zhang, Yimin Chen, Kuang Chen, Xiaodan Xu, Haoxi Zhou, Xu, Xiaodan, Mengchao Cui, Chen, Yimin, Chen, Kuang, Zhou, Haoxi, Cui, Mengchao, Xu, Baixuan, Xiaohui Luan, Zhang, Jinming, Baixuan Xu, Zhang, Xiaojun   +17 more
core   +1 more source

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [¹⁷⁷Lu]Lu-PP-F11N

Pharmaceutics, 2021
The inhibition of the mammalian target of rapamycin complex 1 (mTORC1) by everolimus (RAD001) was recently shown to enhance the tumor uptake of radiolabeled minigastrin.
Michal Grzmil, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé   +5 more
doaj   +1 more source